{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:51:09Z","timestamp":1793987469761,"version":"4.8.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01209-7","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:57:03Z","timestamp":1752137823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants"],"prefix":"10.1038","volume":"10","author":[{"given":"Kirill","family":"Vasilev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Hoxie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Puente-Massaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Yueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disha","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey P.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"1209_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"Y-Q Chen","year":"2018","unstructured":"Chen, Y.-Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429.e10 (2018).","journal-title":"Cell"},{"key":"1209_CR2","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41564-017-0011-8","volume":"2","author":"TJ Wohlbold","year":"2017","unstructured":"Wohlbold, T. J. et al. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nat. Microbiol. 2, 1415\u20131424 (2017).","journal-title":"Nat. Microbiol."},{"key":"1209_CR3","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1093\/cid\/ciz639","volume":"70","author":"HE Maier","year":"2020","unstructured":"Maier, H. E. et al. Pre-existing antineuraminidase antibodies are associated with shortened duration of influenza A(H1N1)pdm virus shedding and illness in naturally infected adults. Clin. Infect. Dis. 70, 2290\u20132297 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1209_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01421-21","volume":"96","author":"J Tan","year":"2022","unstructured":"Tan, J. et al. Human anti-neuraminidase antibodies reduce airborne transmission of clinical influenza virus isolates in the guinea pig model. J. Virol. 96, e0142121 (2022).","journal-title":"J. Virol."},{"key":"1209_CR5","doi-asserted-by":"publisher","first-page":"e00560","DOI":"10.1128\/mBio.00560-19","volume":"10","author":"M McMahon","year":"2019","unstructured":"McMahon, M. et al. Mucosal immunity against neuraminidase prevents influenza B virus transmission in guinea pigs. MBio 10, e00560\u201319 (2019).","journal-title":"MBio"},{"key":"1209_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01057-23","volume":"97","author":"M McMahon","year":"2023","unstructured":"McMahon, M. et al. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner. J. Virol. 97, e0105723 (2023).","journal-title":"J. Virol."},{"key":"1209_CR7","doi-asserted-by":"publisher","unstructured":"Hoy G.et al. Anti-neuraminidase antibodies reduce the susceptibility to and infectivity of influenza A\/H3N2 virus. medRxiv https:\/\/doi.org\/10.1101\/2024.06.14.24308936 (2024).","DOI":"10.1101\/2024.06.14.24308936"},{"key":"1209_CR8","doi-asserted-by":"crossref","unstructured":"Halwe, N. J. et al. Bat-borne H9N2 influenza virus evades MxA restriction and exhibits efficient replication and transmission in ferrets. Nat Commun 15, 3450 (2024).","DOI":"10.1038\/s41467-024-47455-6"},{"key":"1209_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41577-023-00868-8","volume":"23","author":"F Krammer","year":"2023","unstructured":"Krammer, F. & Schultz-Cherry, S. We need to keep an eye on avian influenza. Nat. Rev. Immunol. 23, 267\u2013268 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1209_CR10","doi-asserted-by":"publisher","first-page":"9290","DOI":"10.1128\/JVI.01203-13","volume":"87","author":"H Wan","year":"2013","unstructured":"Wan, H. et al. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J. Virol. 87, 9290\u20139300 (2013).","journal-title":"J. Virol."},{"key":"1209_CR11","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.immuni.2023.07.004","volume":"56","author":"L Hansen","year":"2023","unstructured":"Hansen, L. et al. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity 56, 1927\u20131938.e8 (2023).","journal-title":"Immunity"},{"key":"1209_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7114","volume":"6","author":"H Wan","year":"2015","unstructured":"Wan, H. et al. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Nat. Commun. 6, 6114 (2015).","journal-title":"Nat. Commun."},{"key":"1209_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00332-22","volume":"96","author":"E Kirkpatrick Roubidoux","year":"2022","unstructured":"Kirkpatrick Roubidoux, E. et al. Novel epitopes of the influenza virus N1 neuraminidase targeted by human monoclonal antibodies. J. Virol. 96, e0033222 (2022).","journal-title":"J. Virol."},{"key":"1209_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.virol.2014.02.011","volume":"454-455","author":"X Lu","year":"2014","unstructured":"Lu, X. et al. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus. Virology 454-455, 169\u2013175 (2014).","journal-title":"Virology"},{"key":"1209_CR15","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1128\/JVI.02434-12","volume":"87","author":"S Rockman","year":"2013","unstructured":"Rockman, S. et al. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine. J. Virol. 87, 3053\u20133061 (2013).","journal-title":"J. Virol."},{"key":"1209_CR16","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1016\/j.vaccine.2009.03.021","volume":"27","author":"K Van Reeth","year":"2009","unstructured":"Van Reeth, K. et al. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. Vaccine 27, 6330\u20136339 (2009).","journal-title":"Vaccine"},{"key":"1209_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.virol.2012.06.003","volume":"432","author":"JD Easterbrook","year":"2012","unstructured":"Easterbrook, J. D. et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432, 39\u201344 (2012).","journal-title":"Virology"},{"key":"1209_CR18","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1371\/journal.pmed.0040059","volume":"4","author":"MR Sandbulte","year":"2007","unstructured":"Sandbulte, M. R. et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4, e59 (2007).","journal-title":"PLoS Med."},{"key":"1209_CR19","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1016\/j.vaccine.2012.01.090","volume":"30","author":"Z Chen","year":"2012","unstructured":"Chen, Z., Kim, L., Subbarao, K. & Jin, H. The 2009 pandemic H1N1 virus induces anti-neuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 30, 2516\u20132522 (2012).","journal-title":"Vaccine"},{"key":"1209_CR20","doi-asserted-by":"publisher","first-page":"e26335","DOI":"10.1371\/journal.pone.0026335","volume":"6","author":"G Marcelin","year":"2011","unstructured":"Marcelin, G. et al. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE 6, e26335 (2011).","journal-title":"PLoS ONE"},{"key":"1209_CR21","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1086\/657084","volume":"202","author":"G Marcelin","year":"2010","unstructured":"Marcelin, G. et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J. Infect. Dis. 202, 1634\u20131638 (2010).","journal-title":"J. Infect. Dis."},{"key":"1209_CR22","doi-asserted-by":"publisher","first-page":"e42363","DOI":"10.1371\/journal.pone.0042363","volume":"7","author":"C-Y Wu","year":"2012","unstructured":"Wu, C.-Y. et al. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS ONE 7, e42363 (2012).","journal-title":"PLoS ONE"},{"key":"1209_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.virol.2012.05.006","volume":"430","author":"F-S Quan","year":"2012","unstructured":"Quan, F.-S. et al. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 430, 127\u2013135 (2012).","journal-title":"Virology"},{"key":"1209_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/v15010184","volume":"15","author":"AL Skarlupka","year":"2023","unstructured":"Skarlupka, A. L., Zhang, X., Blas-Machado, U., Sumner, S. F. & Ross, T. M. Multi-influenza HA subtype protection of ferrets vaccinated with an N1 COBRA-based neuraminidase. Viruses 15, 184 (2023).","journal-title":"Viruses"},{"key":"1209_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/intimm\/dxu063","volume":"26","author":"T Azegami","year":"2014","unstructured":"Azegami, T., Yuki, Y. & Kiyono, H. Challenges in mucosal vaccines for the control of infectious diseases. Int Immunol. 26, 517\u2013528 (2014).","journal-title":"Int Immunol."},{"key":"1209_CR26","doi-asserted-by":"publisher","first-page":"16757","DOI":"10.1021\/acsnano.2c06350","volume":"16","author":"JH Lam","year":"2022","unstructured":"Lam, J. H. et al. Artificial cell membrane polymersome-based intranasal Beta spike formulation as a second generation Covid-19 vaccine. ACS Nano 16, 16757\u201316775 (2022).","journal-title":"ACS Nano"},{"key":"1209_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02556-14","volume":"6","author":"TJ Wohlbold","year":"2015","unstructured":"Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio 6, e02556 (2015).","journal-title":"MBio"},{"key":"1209_CR28","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1016\/j.vaccine.2015.08.005","volume":"33","author":"B Kingstad-Bakke","year":"2015","unstructured":"Kingstad-Bakke, B., Kamlangdee, A. & Osorio, J. E. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge. Vaccine 33, 5155\u20135162 (2015).","journal-title":"Vaccine"},{"key":"1209_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj5129","volume":"6","author":"JE Oh","year":"2021","unstructured":"Oh, J. E. et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci. Immunol. 6, eabj5129 (2021).","journal-title":"Sci. Immunol."},{"key":"1209_CR30","doi-asserted-by":"publisher","first-page":"12665","DOI":"10.1128\/JVI.78.22.12665-12667.2004","volume":"78","author":"MN Matrosovich","year":"2004","unstructured":"Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A. & Klenk, H.-D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 78, 12665\u201312667 (2004).","journal-title":"J. Virol."},{"key":"1209_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","volume":"61","author":"P Palese","year":"1974","unstructured":"Palese, P., Tobita, K., Ueda, M. & Compans, R. W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61, 397\u2013410 (1974).","journal-title":"Virology"},{"key":"1209_CR32","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.immuni.2024.05.002","volume":"57","author":"RM Wolters","year":"2024","unstructured":"Wolters, R. M. et al. Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface. Immunity 57, 1413\u20131427.e9 (2024).","journal-title":"Immunity"},{"key":"1209_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133564","volume":"275","author":"M Xue","year":"2024","unstructured":"Xue, M. et al. A Zanamivir-protein conjugate mimicking mucin for trapping influenza virion particles and inhibiting neuraminidase activity. Int J. Biol. Macromol. 275, 133564 (2024).","journal-title":"Int J. Biol. Macromol."},{"key":"1209_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01180-21","volume":"95","author":"A Kawai","year":"2021","unstructured":"Kawai, A. et al. The potential of neuraminidase as an antigen for nasal vaccines to increase cross-protection against influenza viruses. J. Virol. 95, e0118021 (2021).","journal-title":"J. Virol."},{"key":"1209_CR35","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/mi.2014.133","volume":"8","author":"LM Wakim","year":"2015","unstructured":"Wakim, L. M., Smith, J., Caminschi, I., Lahoud, M. H. & Villadangos, J. A. Antibody-targeted vaccination to lung dendritic cells generates tissue-resident memory CD8 T cells that are highly protective against influenza virus infection. Mucosal Immunol. 8, 1060\u20131071 (2015).","journal-title":"Mucosal Immunol."},{"key":"1209_CR36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.immuni.2013.09.013","volume":"39","author":"B Sl\u00fctter","year":"2013","unstructured":"Sl\u00fctter, B., Pewe, L. L., Kaech, S. M. & Harty, J. T. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. Immunity 39, 939\u2013948 (2013).","journal-title":"Immunity"},{"key":"1209_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fimmu.2019.00733","volume":"10","author":"S Takamura","year":"2019","unstructured":"Takamura, S. & Kohlmeier, J. E. Establishment and maintenance of conventional and circulation-driven lung-resident memory CD8+ T cells following respiratory virus infections. Front. Immunol. 10, 733 (2019).","journal-title":"Front. Immunol."},{"key":"1209_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1189\/jlb.0313180","volume":"95","author":"T Wu","year":"2014","unstructured":"Wu, T. et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J. Leukoc. Biol. 95, 215\u2013224 (2014).","journal-title":"J. Leukoc. Biol."},{"key":"1209_CR39","doi-asserted-by":"publisher","first-page":"e66136","DOI":"10.1371\/journal.pone.0066136","volume":"8","author":"J Waithman","year":"2013","unstructured":"Waithman, J. et al. Resident CD8(+) and migratory CD103(+) dendritic cells control CD8 T cell immunity during acute influenza infection. PLoS ONE 8, e66136 (2013).","journal-title":"PLoS ONE"},{"key":"1209_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.602254","volume":"11","author":"E Fisher","year":"2020","unstructured":"Fisher, E. et al. Induction of SARS-CoV-2 protein S-specific CD8+ T cells in the lungs of gp96-Ig-S vaccinated mice. Front. Immunol. 11, 602254 (2020).","journal-title":"Front. Immunol."},{"key":"1209_CR41","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3389\/fimmu.2018.01860","volume":"9","author":"MM Wilk","year":"2018","unstructured":"Wilk, M. M. & Mills, K. H. G. CD4 TRM cells following infection and immunization: Implications for more effective vaccine design. Front. Immunol. 9, 1860 (2018).","journal-title":"Front. Immunol."},{"key":"1209_CR42","doi-asserted-by":"publisher","first-page":"e1009168","DOI":"10.1371\/journal.ppat.1009168","volume":"17","author":"W Lee","year":"2021","unstructured":"Lee, W. et al. Carbomer-based adjuvant elicits CD8 T-cell immunity by inducing a distinct metabolic state in cross-presenting dendritic cells. PLoS Pathog. 17, e1009168 (2021).","journal-title":"PLoS Pathog."},{"key":"1209_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00486-w","volume":"7","author":"S Strohmeier","year":"2022","unstructured":"Strohmeier, S. et al. A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. NPJ Vaccin.7, 81 (2022).","journal-title":"NPJ Vaccin."},{"key":"1209_CR44","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/vim.2017.0026","volume":"30","author":"T Aoshi","year":"2017","unstructured":"Aoshi, T. Modes of action for mucosal vaccine adjuvants. Viral Immunol. 30, 463\u2013470 (2017).","journal-title":"Viral Immunol."},{"key":"1209_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.7774\/cevr.2022.11.3.235","volume":"11","author":"R Anggraeni","year":"2022","unstructured":"Anggraeni, R., Ana, I. D. & Wihadmadyatami, H. Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants. Clin. Exp. Vaccin. Res. 11, 235\u2013248 (2022).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"1209_CR46","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-021-00583-2","volume":"22","author":"EC Lavelle","year":"2022","unstructured":"Lavelle, E. C. & Ward, R. W. Mucosal vaccines - fortifying the frontiers. Nat. Rev. Immunol. 22, 236\u2013250 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1209_CR47","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/0264-410X(95)00127-M","volume":"13","author":"ED Kilbourne","year":"1995","unstructured":"Kilbourne, E. D. et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13, 1799\u20131803 (1995).","journal-title":"Vaccine"},{"key":"1209_CR48","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/0264-410X(95)00126-L","volume":"13","author":"M Hocart","year":"1995","unstructured":"Hocart, M. et al. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 13, 1793\u20131798 (1995).","journal-title":"Vaccine"},{"key":"1209_CR49","doi-asserted-by":"publisher","unstructured":"Krammer F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? MBio 9 https:\/\/doi.org\/10.1128\/mBio.02332-17 (2018).","DOI":"10.1128\/mBio.02332-17"},{"key":"1209_CR50","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0264-410X(97)00279-X","volume":"16","author":"BE Johansson","year":"1998","unstructured":"Johansson, B. E., Matthews, J. T. & Kilbourne, E. D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16, 1009\u20131015 (1998).","journal-title":"Vaccine"},{"key":"1209_CR51","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0264-410X(01)00490-X","volume":"20","author":"BE Johansson","year":"2002","unstructured":"Johansson, B. E., Pokorny, B. A. & Tiso, V. A. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 20, 1670\u20131674 (2002).","journal-title":"Vaccine"},{"key":"1209_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4161\/hv.4.6.6201","volume":"4","author":"BE Johansson","year":"2008","unstructured":"Johansson, B. E. & Brett, I. C. Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines. Hum. Vaccin. 4, 420\u2013424 (2008).","journal-title":"Hum. Vaccin."},{"key":"1209_CR53","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1128\/JVI.01035-10","volume":"84","author":"BJ Bosch","year":"2010","unstructured":"Bosch, B. J. et al. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84, 10366\u201310374 (2010).","journal-title":"J. Virol."},{"key":"1209_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01011-x","volume":"9","author":"G Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s, G. et al. Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines. NPJ Vaccin. 9, 228 (2024).","journal-title":"NPJ Vaccin."},{"key":"1209_CR55","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02241-21","volume":"12","author":"S Strohmeier","year":"2021","unstructured":"Strohmeier, S. et al. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. MBio 12, e0224121 (2021).","journal-title":"MBio"},{"key":"1209_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126269","volume":"42","author":"I Hoxie","year":"2024","unstructured":"Hoxie, I. et al. A recombinant N2 neuraminidase-based CpG 1018\u00ae adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters. Vaccine 42, 126269 (2024).","journal-title":"Vaccine"},{"key":"1209_CR57","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1016\/S0264-410X(03)00387-6","volume":"21","author":"T Jones","year":"2003","unstructured":"Jones, T. et al. A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine 21, 3706\u20133712 (2003).","journal-title":"Vaccine"},{"key":"1209_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163089","volume":"11","author":"R Lambkin-Williams","year":"2016","unstructured":"Lambkin-Williams, R. et al. An intranasal Proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic & efficacious in the human viral influenza challenge model. Serum IgG & mucosal IgA are important correlates of protection against illness associated with infection. PLoS ONE 11, e0163089 (2016).","journal-title":"PLoS ONE"},{"key":"1209_CR59","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1016\/j.vaccine.2017.05.004","volume":"35","author":"W Cao","year":"2017","unstructured":"Cao, W. et al. Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice. Vaccine 35, 3318\u20133325 (2017).","journal-title":"Vaccine"},{"key":"1209_CR60","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1016\/j.vaccine.2004.03.035","volume":"22","author":"T Jones","year":"2004","unstructured":"Jones, T. et al. Protollin: a novel adjuvant for intranasal vaccines. Vaccine 22, 3691\u20133697 (2004).","journal-title":"Vaccine"},{"key":"1209_CR61","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1128\/CVI.05441-11","volume":"19","author":"M Baz","year":"2012","unstructured":"Baz, M. et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A\/H3N2 influenza vaccines in mice. Clin. Vaccin. Immunol. 19, 209\u2013218 (2012).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1209_CR62","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1016\/j.vaccine.2014.08.029","volume":"32","author":"J Ann","year":"2014","unstructured":"Ann, J. et al. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines. Vaccine 32, 5730\u20135739 (2014).","journal-title":"Vaccine"},{"key":"1209_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13819-5","volume":"12","author":"FC Stark","year":"2022","unstructured":"Stark, F. C. et al. Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. Sci. Rep. 12, 9772 (2022).","journal-title":"Sci. Rep."},{"key":"1209_CR64","doi-asserted-by":"publisher","first-page":"e0150606","DOI":"10.1371\/journal.pone.0150606","volume":"11","author":"Y-RA Yu","year":"2016","unstructured":"Yu, Y.-R. A. et al. A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed Murine non-lymphoid tissues. PLoS ONE 11, e0150606 (2016).","journal-title":"PLoS ONE"},{"key":"1209_CR65","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1016\/j.vaccine.2023.10.005","volume":"41","author":"P Kitikoon","year":"2023","unstructured":"Kitikoon, P. et al. Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection. Vaccine 41, 6941\u20136951 (2023).","journal-title":"Vaccine"},{"key":"1209_CR66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/vaccines9040404","volume":"9","author":"S Strohmeier","year":"2021","unstructured":"Strohmeier, S., Carre\u00f1o, J. M., Brito, R. N. & Krammer, F. Introduction of cysteines in the stalk domain of recombinant influenza virus N1 neuraminidase enhances protein stability and immunogenicity in mice. Vaccines (Basel) 9, 404 (2021).","journal-title":"Vaccines (Basel)"},{"key":"1209_CR67","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/1743-422X-8-251","volume":"8","author":"K Harris","year":"2011","unstructured":"Harris, K., Ream, R., Gao, J. & Eichelberger, M. C. Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virol. J. 8, 251 (2011).","journal-title":"Virol. J."},{"key":"1209_CR68","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0264-410X(99)00334-5","volume":"18","author":"JJ Treanor","year":"1999","unstructured":"Treanor, J. J. et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18, 899\u2013906 (1999).","journal-title":"Vaccine"},{"key":"1209_CR69","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1215817","volume":"369","author":"VK Jain","year":"2013","unstructured":"Jain, V. K. et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N. Engl. J. Med. 369, 2481\u20132491 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1209_CR70","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJMoa065368","volume":"356","author":"RB Belshe","year":"2007","unstructured":"Belshe, R. B. et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356, 685\u2013696 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1209_CR71","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpeds.2007.04.024","volume":"151","author":"K Lin","year":"2007","unstructured":"Lin, K. Intranasal influenza vaccine may be a safe, effective option for many children. J. Pediatr. 151, 102\u2013103 (2007).","journal-title":"J. Pediatr."},{"key":"1209_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568978","volume":"11","author":"EA Bonney","year":"2020","unstructured":"Bonney, E. A. et al. Protective intranasal immunization against influenza virus in infant mice is dependent on IL-6. Front. Immunol. 11, 568978 (2020).","journal-title":"Front. Immunol."},{"key":"1209_CR73","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2019.00646","volume":"10","author":"Y Bhide","year":"2019","unstructured":"Bhide, Y. et al. Cross-protective potential and protection-relevant immune mechanisms of whole inactivated influenza virus vaccines are determined by adjuvants and route of immunization. Front. Immunol. 10, 646 (2019).","journal-title":"Front. Immunol."},{"key":"1209_CR74","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1128\/JVI.02598-15","volume":"90","author":"AB Ryder","year":"2015","unstructured":"Ryder, A. B. et al. Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains. J. Virol. 90, 2544\u20132550 (2015).","journal-title":"J. Virol."},{"key":"1209_CR75","doi-asserted-by":"publisher","first-page":"L833","DOI":"10.1152\/ajplung.00173.2001","volume":"282","author":"DS Southam","year":"2002","unstructured":"Southam, D. S., Dolovich, M., O\u2019Byrne, P. M. & Inman, M. D. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L833\u2013L839 (2002).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1209_CR76","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/j.vaccine.2014.02.019","volume":"32","author":"C Keijzer","year":"2014","unstructured":"Keijzer, C. et al. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion. Vaccine 32, 2904\u20132910 (2014).","journal-title":"Vaccine"},{"key":"1209_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1476-8518-8-4","volume":"8","author":"NF Eng","year":"2010","unstructured":"Eng, N. F., Garlapati, S., Gerdts, V., Babiuk, L. A. & Mutwiri, G. K. PCEP enhances IgA mucosal immune responses in mice following different immunization routes with influenza virus antigens. J. Immune Based Ther. Vaccin. 8, 4 (2010).","journal-title":"J. Immune Based Ther. Vaccin."},{"key":"1209_CR78","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/imcb.12324","volume":"98","author":"BS Goldberg","year":"2020","unstructured":"Goldberg, B. S. & Ackerman, M. E. Antibody-mediated complement activation in pathology and protection. Immunol. Cell Biol. 98, 305\u2013317 (2020).","journal-title":"Immunol. Cell Biol."},{"key":"1209_CR79","doi-asserted-by":"publisher","unstructured":"Wittwer, K. et al. Non-neutralizing antibody responses to vesicular stomatitis virus-vectored influenza A virus vaccines correlate with protection. bioRxiv https:\/\/doi.org\/10.1101\/2022.11.02.514911 (2022).","DOI":"10.1101\/2022.11.02.514911"},{"key":"1209_CR80","doi-asserted-by":"publisher","first-page":"e1009724","DOI":"10.1371\/journal.ppat.1009724","volume":"17","author":"Y-A Ko","year":"2021","unstructured":"Ko, Y.-A. et al. A non-neutralizing antibody broadly protects against influenza virus infection by engaging effector cells. PLoS Pathog. 17, e1009724 (2021).","journal-title":"PLoS Pathog."},{"key":"1209_CR81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2019.06.018","volume":"34","author":"ASO Dias","year":"2019","unstructured":"Dias, A. S. O. et al. TLR-2 and TLR-4 agonists favor expansion of CD4+ T cell subsets implicated in the severity of neuromyelitis optica spectrum disorders. Mult. Scler. Relat. Disord. 34, 66\u201376 (2019).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1209_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823058","volume":"13","author":"A Novak","year":"2022","unstructured":"Novak, A. et al. Activation of canine, mouse and human TLR2 and TLR4 by inactivated Leptospira vaccine strains. Front. Immunol. 13, 823058 (2022).","journal-title":"Front. Immunol."},{"key":"1209_CR83","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1073\/pnas.1115369109","volume":"109","author":"T Onodera","year":"2012","unstructured":"Onodera, T. et al. Memory B cells in the lung participate in protective humoral immune responses to pulmonary influenza virus reinfection. Proc. Natl Acad. Sci. USA 109, 2485\u20132490 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1209_CR84","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.4049\/jimmunol.175.8.4904","volume":"175","author":"J Rangel-Moreno","year":"2005","unstructured":"Rangel-Moreno, J. et al. Role of CXC chemokine ligand 13, CC chemokine ligand (CCL) 19, and CCL21 in the organization and function of nasal-associated lymphoid tissue. J. Immunol. 175, 4904\u20134913 (2005).","journal-title":"J. Immunol."},{"key":"1209_CR85","doi-asserted-by":"publisher","first-page":"e40733","DOI":"10.1371\/journal.pone.0040733","volume":"7","author":"AW Boyden","year":"2012","unstructured":"Boyden, A. W., Legge, K. L. & Waldschmidt, T. J. Pulmonary infection with influenza A virus induces site-specific germinal center and T follicular helper cell responses. PLoS ONE 7, e40733 (2012).","journal-title":"PLoS ONE"},{"key":"1209_CR86","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1016\/j.vaccine.2012.03.035","volume":"30","author":"LE Richert","year":"2012","unstructured":"Richert, L. E. et al. A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine 30, 3653\u20133665 (2012).","journal-title":"Vaccine"},{"key":"1209_CR87","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1128\/JVI.02455-14","volume":"89","author":"Y Wu","year":"2015","unstructured":"Wu, Y. et al. Lethal coinfection of influenza virus and Streptococcus pneumoniae lowers antibody response to influenza virus in lung and reduces numbers of germinal center B cells, T follicular helper cells, and plasma cells in mediastinal lymph Node. J. Virol. 89, 2013\u20132023 (2015).","journal-title":"J. Virol."},{"key":"1209_CR88","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.4049\/jimmunol.173.3.1978","volume":"173","author":"KB Renegar","year":"2004","unstructured":"Renegar, K. B., Small, P. A. Jr, Boykins, L. G. & Wright, P. F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173, 1978\u20131986 (2004).","journal-title":"J. Immunol."},{"key":"1209_CR89","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/imr.12662","volume":"284","author":"AJ Sant","year":"2018","unstructured":"Sant, A. J., DiPiazza, A. T., Nayak, J. L., Rattan, A. & Richards, K. A. CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential. Immunol. Rev. 284, 91\u2013105 (2018).","journal-title":"Immunol. Rev."},{"key":"1209_CR90","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1082305","volume":"300","author":"DJ Shedlock","year":"2003","unstructured":"Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337\u2013339 (2003).","journal-title":"Science"},{"key":"1209_CR91","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1172\/JCI63689","volume":"122","author":"KK McKinstry","year":"2012","unstructured":"McKinstry, K. K. et al. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J. Clin. Invest 122, 2847\u20132856 (2012).","journal-title":"J. Clin. Invest"},{"key":"1209_CR92","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1016\/j.vaccine.2018.06.007","volume":"36","author":"SA Valkenburg","year":"2018","unstructured":"Valkenburg, S. A. et al. Protection by universal influenza vaccine is mediated by memory CD4 T cells. Vaccine 36, 4198\u20134206 (2018).","journal-title":"Vaccine"},{"key":"1209_CR93","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijid.2014.05.016","volume":"27","author":"J Li","year":"2014","unstructured":"Li, J., Ar\u00e9valo, M. T., Chen, Y., Chen, S. & Zeng, M. T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine. Int J. Infect. Dis. 27, 37\u201343 (2014).","journal-title":"Int J. Infect. Dis."},{"key":"1209_CR94","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.3389\/fimmu.2018.02312","volume":"9","author":"W Dong","year":"2018","unstructured":"Dong, W. et al. Cross-protective immune responses induced by sequential influenza virus infection and by sequential vaccination with inactivated influenza vaccines. Front. Immunol. 9, 2312 (2018).","journal-title":"Front. Immunol."},{"key":"1209_CR95","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nm.2612","volume":"18","author":"TM Wilkinson","year":"2012","unstructured":"Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18, 274\u2013280 (2012).","journal-title":"Nat. Med."},{"key":"1209_CR96","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305\u20131312 (2013).","journal-title":"Nat. Med."},{"key":"1209_CR97","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.chom.2021.10.009","volume":"29","author":"DR McIlwain","year":"2021","unstructured":"McIlwain, D. R. et al. Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell Host Microbe 29, 1828\u20131837.e5 (2021).","journal-title":"Cell Host Microbe"},{"key":"1209_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2024.101409","volume":"66","author":"C Ruscitti","year":"2024","unstructured":"Ruscitti, C., Radermecker, C. & Marichal, T. Journey of monocytes and macrophages upon influenza A virus infection. Curr. Opin. Virol. 66, 101409 (2024).","journal-title":"Curr. Opin. Virol."},{"key":"1209_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1260543","volume":"14","author":"H Li","year":"2023","unstructured":"Li, H., Wang, A., Zhang, Y. & Wei, F. Diverse roles of lung macrophages in the immune response to influenza A virus. Front. Microbiol. 14, 1260543 (2023).","journal-title":"Front. Microbiol."},{"key":"1209_CR100","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/eji.201242620","volume":"43","author":"G Zhou","year":"2013","unstructured":"Zhou, G., Juang, S. W. W. & Kane, K. P. NK cells exacerbate the pathology of influenza virus infection in mice. Eur. J. Immunol. 43, 929\u2013938 (2013).","journal-title":"Eur. J. Immunol."},{"key":"1209_CR101","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/infdis\/jis340","volume":"206","author":"MF Abdul-Careem","year":"2012","unstructured":"Abdul-Careem, M. F. et al. Critical role of natural killer cells in lung immunopathology during influenza infection in mice. J. Infect. Dis. 206, 167\u2013177 (2012).","journal-title":"J. Infect. Dis."},{"key":"1209_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2021.101495","volume":"70","author":"E Aleebrahim-Dehkordi","year":"2022","unstructured":"Aleebrahim-Dehkordi, E. et al. T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transpl. Immunol. 70, 101495 (2022).","journal-title":"Transpl. Immunol."},{"key":"1209_CR103","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01725-21","volume":"96","author":"JB Kimble","year":"2022","unstructured":"Kimble, J. B. et al. Vaccine-associated enhanced respiratory disease following influenza virus infection in ferrets recapitulates the model in pigs. J. Virol. 96, e0172521 (2022).","journal-title":"J. Virol."},{"key":"1209_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1217181","volume":"14","author":"LA Chang","year":"2023","unstructured":"Chang, L. A. et al. Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia. Front. Immunol. 14, 1217181 (2023).","journal-title":"Front. Immunol."},{"key":"1209_CR105","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1128\/JVI.06053-11","volume":"86","author":"Y Hu","year":"2012","unstructured":"Hu, Y. et al. Mast cell-induced lung injury in mice infected with H5N1 influenza virus. J. Virol. 86, 3347\u20133356 (2012).","journal-title":"J. Virol."},{"key":"1209_CR106","doi-asserted-by":"crossref","unstructured":"Lv, H. et al. Differential antigenic imprinting effects between influenza H1N1 hemagglutinin and neuraminidase in a mouse model. J. Virol. 99, e0169524. (2024)","DOI":"10.1101\/2024.04.17.589918"},{"key":"1209_CR107","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.4049\/jimmunol.139.6.2010","volume":"139","author":"BE Johansson","year":"1987","unstructured":"Johansson, B. E., Moran, T. M., Bona, C. A., Popple, S. W. & Kilbourne, E. D. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 139, 2010\u20132014 (1987).","journal-title":"J. Immunol."},{"key":"1209_CR108","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3389\/fimmu.2020.01166","volume":"11","author":"A Choi","year":"2020","unstructured":"Choi, A. et al. Non-sterilizing, infection-permissive vaccination with inactivated influenza virus vaccine reshapes subsequent virus infection-induced protective heterosubtypic immunity from cellular to humoral cross-reactive immune responses. Front. Immunol. 11, 1166 (2020).","journal-title":"Front. Immunol."},{"key":"1209_CR109","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-1-0716-3666-4_4","volume":"2762","author":"M Loganathan","year":"2024","unstructured":"Loganathan, M., Francis, B. & Krammer, F. Production of influenza virus glycoproteins using insect cells. Methods Mol. Biol. 2762, 43\u201370 (2024).","journal-title":"Methods Mol. Biol."},{"key":"1209_CR110","doi-asserted-by":"crossref","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. 81, e51112 (2013).","DOI":"10.3791\/51112"},{"key":"1209_CR111","unstructured":"Compositions and methods for activating innate and allergic immunity. https:\/\/patents.justia.com\/patent\/9433672 (accessed 12 Dec 2024)."},{"key":"1209_CR112","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35586-7","volume":"13","author":"D Stadlbauer","year":"2022","unstructured":"Stadlbauer, D. et al. Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site. Nat. Commun. 13, 7864 (2022).","journal-title":"Nat. Commun."},{"key":"1209_CR113","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0022-1759(96)00243-8","volume":"202","author":"H Asanuma","year":"1997","unstructured":"Asanuma, H. et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods 202, 123\u2013131 (1997).","journal-title":"J. Immunol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01209-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01209-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01209-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:48:29Z","timestamp":1757224109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01209-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1209"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01209-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines and influenza virus therapeutics which list F.K. as co-inventor and F.K. has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. F.K. is co-founder and scientific advisory board member of Castlevax. F.K. has consulted for Merck, GSK, Sanofi, Curevac, Gritstone, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics. C.P.M. is an employee of the GSK group of companies and owns shares in GSK. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}